Research Article

The Application of a Three-Step Proteome Analysis for Identification of New Biomarkers of Pancreatic Cancer

Table 3

(a) Serum tumor marker levels in patients with pancreatic cancer.

GenderAge (years)UICC-stageTumor size (mm)CA19-9 (U/mL)CEA (ng/mL)ApoA-IV (AU)GC (AU)RBP4 (AU)

M38IA1026.22.3262.1 35.9 54.2
M50IB3046.52.38.534.3 43.9
M63IIA181571.110.226.7 37.0
M*62IIA389570.725.1 41.5
M*54IIA24111.487.5 11.3 42.5
M73IIA2515.53.5203.513.6 49.5
F*76IIA2613.31.570.7 33.1 43.2
M65IIB3215793.4352.1 24.3 36.7
M*74IIB2710.93.40 28.0 35.3
F74IIB40433.254 25.8 38.9
F68IIB273022.182.840.8 36.4
M61IIB30101.4134.7 27.346.2
M63IIB151080144.623.9 53.3
M*73IIB5013.92.123.21.8 43.1
F62IIB2511.51.1111.728.4 43.1

Ave ± SD

CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protein, RBP4: plasma retinol binding protein 4.
The stars indicate the patient who had a normal CA19-9 level and a low ApoA-IV.
Ave: average. SD: standard deviation. AU: arbitrary unit.
(b) Serum tumor marker levels in healthy controls.

GenderAge (years)CA19-9 (u/mL)CEA (ng/mL)ApoA-IV (AU)GC (AU)RBP4 (AU)

M7133.92.2157.429.547.7
M550.14.7243.835.048.5
M556.41223.035.354.3
M550.13.5237.133.048.1
M607.70.8237.123.944.1
M6037.47214.039.648.8
M617.64.8277.016.849.7
F777.11.1294.524.243.7
M617.81.380.633.455.3
F6163210.145.856.3
F652.92.165.761.753.3
M665.10.7156.733.844.7
F6211.71.7122.933.050.9
F648.41.2222.938.750.3
F7124.42.6184.730.556.3

Ave ± SD

CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protien, RBP4: plasma retinol binding protein
Ave: average. SD: standard deviation. AU: arbitrary unit.